MedinCell

4:30 PM - 4:45 PM, Monday, June 3, 2019 ・ Theater 1
MedinCell is a clinical stage pharmaceutical company developing long acting injectables based on BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. Independently and in partnership with other pharma or NGOs MedinCell develop a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action and ease of use. BEPO® physicochemical properties make it an ideal vehicle for a broad variety of compounds such as peptides and small molecules. BEPO® applications cover a wide range of unmet medical needs. In many situations, such as life cycle management, we can develop multiple duration prototypes to provide partners with greater strategic flexibility and competitive advantage. Medincell is dedicated to delivering innovative medical treatments to all global markets. Via its active Global Health strategy, MedinCell aims to engage like-minded stakeholders where we can make a difference.
Ticker:
MEDCL
Exchange:
Euronext Paris
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
France
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
mdc-IRM
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6
Speaker
photo
Head of Business Development, US, Japan and South Korea
MedinCell